恩华药业：获得右酮洛芬氨丁三醇注射液《药品注册证书》

Core Viewpoint - The company has received approval from the National Medical Products Administration for the injection of Ketorolac Tromethamine, enhancing its product pipeline and market competitiveness [1] Group 1: Product Approval - The approved product is a chemical drug, specifically an injection formulation of Ketorolac Tromethamine, with a specification of 2ml:50mg [1] - The drug is indicated for acute moderate to severe postoperative pain in adults who are unsuitable for oral administration [1] - The product has a shelf life of 24 months, with the approval valid until January 13, 2031 [1] Group 2: Market Impact - This marks the company's first non-steroidal anti-inflammatory drug (NSAID) for perioperative injection, which is expected to enrich its product line [1] - The introduction of this drug is anticipated to enhance the company's market competitiveness and overall performance [1] - However, the production and sales may be influenced by uncertain factors [1]